Subscribe to RSS
DOI: 10.1055/a-2343-4386
Erratum: Aktuelle und zukünftige pharmakologische Therapieoptionen zur Behandlung der Osteoporose und deren Wirkmechanismen – ein Überblick
Correction: An Introduction to Current and Future Pharmacological Therapy Options and their Mechanisms of Action![](https://www.thieme-connect.de/media/10.1055-s-00034914/202403/lookinside/thumbnails/err0086-01-2024_10-1055-a-2343-4386-1.jpg)
Erratum
Aktuelle und zukünftige pharmakologische Therapieoptionen zur Behandlung der Osteoporose und deren Wirkmechanismen – ein Überblick
Fößl I, Obermayer-Pietsch B. Osteologie 2024; 33: 67–73.
DOI: 10.1055/a-2304-7012
Im oben genannten Artikel ist die Tab. 1 fehlerhaft. Die korrekte Tabelle ist unten abgebildet.
Substanz |
Dosierung |
Applikation |
Effekt auf vertebrale Frakturen |
Effekt auf non-vertebrale Frakturen |
Effekt auf Frakturen der Hüfte |
Relevanteste Sicherheits-aspekte |
Zulassung für |
Referenzen |
---|---|---|---|---|---|---|---|---|
Alendronata |
10mg täglich; |
Oral |
+ |
+ |
+ |
Reizungen der Magenschleimhaut, Anstieg von Kreatinin, MRONJ, AFF |
Frauen und Männer; GIOP |
|
Risedronata |
5mg täglich; |
Oral |
+ |
+ |
+ |
Frauen und Männer |
||
Ibandronatb |
3mg alle 3 Monate intravenös oder 150mg einmal monatlich oral |
Intravenös oder oral |
+ |
+ |
- |
Frauen |
||
Zoledronat |
5mg |
Intravenös |
+ |
+ |
+ |
Frauen und Männer; GIOP; Morbus Paget |
||
Raloxifen |
60 mg |
Oral |
+ |
+ c |
- |
Hitzewallungen, tiefe Venenthrombosen, Lungenembolien, Netzhautvenenthrombosen |
Frauen |
|
Bazedoxifen |
20 mg |
Oral |
+ |
+ / - d |
- |
Frauen |
||
Teriparatid |
20 µg täglich für max 2 years |
Subkutan |
+ |
+ |
- |
Hyperkalzämie, Hyperkalziurie, Hyperurikämie,
|
Frauen und Männer; GIOP |
[21, 85] |
Abaloparatid |
80 µg täglich bei maximal totaler Verabreichungsdauer von 18 Monaten |
Subkutan |
+ |
+ |
+ |
In der EU zugelassen für Frauen; in den USA zugelassen für Frauen und Männer |
||
Denosumab |
60mg alle 6 Monate |
Subkutan |
+ |
+ |
+ |
Hypokalzämie, Wirbelfrakturen, MRONJ, AFF, Nierenschädigung, Hautinfektionen |
Frauen und Männer, MHA, GIOP |
|
Romosozumab |
210mg monatlich für 1 Jahr |
Subkutan |
+ |
+ |
+ |
Kardiovaskuläre (im Vergleich mit Alendronat) |
Frauen |
|
MHT / HRTf |
Abhängig vom Therapieziel |
Abhängig von Substanz und Indikation |
+ |
+ |
+ |
Venöse Thromboembolien, Lungenembolien, Brustkrebs |
NA |
+ Die Substanz zeigt eine Wirkung auf die jeweilige Fraktur; - die Substanz zeigt keine bekannte Wirkung auf die jeweilige Fraktur; ± die Substanz zeigt kontroverse Studienergebnisse in Bezug auf die jeweilige Fraktur. AFF, atypische Femurfraktur; EU, Europäische Union; GIOP, Glukokortikoid-induzierte Osteoporose; HRT, Hormonersatztherapie; MHA, Knochenverlust in Verbindung mit Hormonablation bei Männern mit Prostatakrebs und erhöhtem Frakturrisiko; MHT, postmenopausale Hormontherapie; MRONJ, medikamentenbedingte Osteonekrose des Kiefers. aKeine direkten Belege für die frakturhemmende Wirksamkeit bei einmal wöchentlicher Verabreichung. bKeine direkten Belege für die frakturhemmende Wirksamkeit bei vierteljährlicher intravenöser Verabreichung von 3 mg. cBei PatientInnen mit vorbestehender schwerer Wirbelfraktur. dKontroverse Ergebnisse.. fFrakturinzidenz kein primärer Endpunkt.
Publication History
Article published online:
26 July 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 64 Liberman UA, Weiss SR, Bröll J. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1444 DOI: 10.1056/NEJM199511303332201.
- 65 Schnitzer T, Bone HG, Crepaldi G. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12: 1-12 DOI: 10.1007/BF03339822/METRICS.
- 66 Black DM, Cummings SR, Karpf DB. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541 DOI: 10.1016/S0140-6736(96)07088-2.
- 67 Axelsson KF, Wallander M, Johansson H. et al. Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med 2017; 282: 546-559 DOI: 10.1111/JOIM.12678.
- 68 McClung MR, Balske A, Burgio DE. et al. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int 2013; 24: 301-310 DOI: 10.1007/S00198-012-2175-7.
- 69 McClung MR, Geusens P, Miller PD. et al. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. N Engl J Med 2001; 344: 333-340 DOI: 10.1056/nejm200102013440503.
- 70 Reginster JY, Minne HW, Sorensen OH. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91 DOI: 10.1007/S001980050010.
- 71 Harris ST, Watts NB, Genant HK. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352 DOI: 10.1001/JAMA.282.14.1344.
- 72 Miller PD, Recker RR, Harris S. et al. Long-term fracture rates seen with continued ibandronate treatment: Pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 2014; 25: 349-357 DOI: 10.1007/S00198-013-2518-Z/METRICS.
- 73 Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. In: Current Medical Research and Opinion. Taylor & Francis; 2008: 237-245
- 74 Delmas PD, Recker RR, Chesnut CH. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15: 792-798 DOI: 10.1007/S00198-004-1602-9.
- 75 Chesnut CH, Skag A, Christiansen C. et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res 2004; 19: 1241-1249 DOI: 10.1359/JBMR.040325.
- 76 Black DM, Delmas PD, Eastell R. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med 2007; 356: 1809-1822 DOI: 10.1056/nejmoa067312.
- 77 Lyles KW, Colón-Emeric CS, Magaziner JS. et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007; 357: 1799-1809 DOI: 10.1056/NEJMOA074941/SUPPL_FILE/NEJMOA074941_SA3.PDF.
- 78 Recker RR, Kendler D, Recknor CP. et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007; 40: 843-851 DOI: 10.1016/J.BONE.2006.11.001.
- 79 Delmas PD, Genant HK, Crans GG. et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone 2003; 33: 522-532 DOI: 10.1016/S8756-3282(03)00241-2.
- 80 Ettinger B, Black DM, Mitlak BH. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645 DOI: 10.1001/JAMA.282.7.637.
- 81 Ellis AG, Reginster JY, Luo X. et al. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Curr Med Res Opin 2014; 30: 1617-1626 DOI: 10.1185/03007995.2014.908279.
- 82 Ellis AG, Reginster JY, Luo X. et al. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value Health 2014; 17: 424-432 DOI: 10.1016/J.JVAL.2014.01.008.
- 83 De Villiers TJ, Chines AA, Palacios S. et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567-576 DOI: 10.1007/S00198-010-1302-6.
- 84 Kanis JA, Johansson H, Oden A. et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009; 44: 1049-1054 DOI: 10.1016/J.BONE.2009.02.014.
- 85 Kendler DL, Marin F, Zerbini CAF. et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391: 230-240 DOI: 10.1016/S0140-6736(17)32137-2.
- 86 Reginster JY, Bianic F, Campbell R. et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 2019; 30: 1465-1473 DOI: 10.1007/s00198-019-04947-2.
- 87 McCloskey EV, Fitzpatrick LA, Hu MY. et al. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos 2019; 14 DOI: 10.1007/S11657-019-0564-7.
- 88 Miller PD, Hattersley G, Riis BJ. et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 2016; 316: 722-733 DOI: 10.1001/JAMA.2016.11136.
- 89 Cosman F, Cooper C, Wang Y. et al. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporos Int 2022; 33: 1703-1714 DOI: 10.1007/s00198-022-06413-y.
- 90 Cummings SR, Martin JS, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765 DOI: 10.1056/NEJMOA0809493.
- 91 Broadwell A, Chines A, Ebeling PR. et al. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. J Clin Endocrinol Metab 2021; 106: 397-409 DOI: 10.1210/CLINEM/DGAA851.
- 92 Geusens P, Oates M, Miyauchi A. et al. The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study. JBMR Plus 2019; 3 DOI: 10.1002/JBM4.10211.
- 93 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377: 1417-1427 DOI: 10.1056/nejmoa1708322.
- 94 Zhu L, Jiang X, Sun Y. et al. Effect of hormone therapy on the risk of bone fractures: A systematic review and meta-analysis of randomized controlled trials. Menopause 2016; 23: 461-470 DOI: 10.1097/GME.0000000000000519.
- 95 Bagger YZ, Tankó LB, Alexandersen P. et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728-735 DOI: 10.1016/J.BONE.2003.12.021.
- 96 Banks E, Beral V, Reeves G. et al. Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women. JAMA 2004; 291: 2212-2220 DOI: 10.1001/JAMA.291.18.2212.
- 97 Anderson GL, Limacher M, Assaf AR. et al. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-1712 DOI: 10.1001/JAMA.291.14.1701.
- 98 Rossouw JE, Anderson GL, Prentice RL. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333 DOI: 10.1001/JAMA.288.3.321.
- 99 Hadji P, Ryan KA, Yu CR. et al. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis. Climacteric 2016; 19: 482-487 DOI: 10.1080/13697137.2016.1216958.
- 100 Cauley JA, Robbins J, Chen Z. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1729-1738 DOI: 10.1001/JAMA.290.13.1729.
- 101 Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891-2897 DOI: 10.1001/JAMA.285.22.2891.